A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Recruiting · NCT07407933 · Interventional (participants receive a specific treatment) · Lead sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalation in participants with previously untreated ES-SCLC to determine the safety and tolerability of YL201 in combination with fixed dose of atezolizumab. The planned dose levels of YL201 are 1.2 mg/kg, 1.6 mg/kg and 2.0 mg/kg. Part 2 consists of a dose optimization stage followed by a dose expansion stage. During the dose optimization stage, participants will be randomized 1:1:1 to receive either YL201 at 1.2 mg/kg,1.6 mg/kg or 2.0 mg/kg Q3W in combination with fixed dose of atezolizumab. The decision to initiate the dose expansion stage in Part 2 and choose one or two of the YL201 dose level(s) will be based on the review of safety, PK, and efficacy from the dose optimization stage. Treatment will continue until disease progression, unacceptable toxicity, or withdraw of consent.
Who can take part
Inclusion criteria
- years of age or older. 2. Histologically or cytologically confirmed diagnosis of ES-SCLC 3. Eastern Cooperative Oncology Group performance status of 0 or 1 4. Adequate hematologic and end-organ function
Exclusion criteria
- No prior systemic anti-cancer treatment for ES-SCLC
- No prior treatment targeting B7H3 or topoisomerase I inhibitor
- No clinically active brain metastases or spinal cord compression
- No current or history of interstitial lung disease (ILD)/ pneumonitis
- No clinically significant cardiovascular disease (eg, New York Heart Association class II to IV congestive heart failure)
- ther protocol-defined inclusion/ exclusion criteria may apply.
Where it is running
22 locations listed across 4 US states.
- Site 1001 - Washington D.C., District of Columbia, United States
- Site 1004 - Louisville, Kentucky, United States
- Site 1005 - Houston, Texas, United States
- Site 1002 - Fairfax, Virginia, United States
- Site 2013 - Badajoz, Spain
- Site 2014 - Barcelona, Spain
- Site 2003 - Barcelona, Spain
- Site 1901 - Craiova, Romania
- Site 2201 - London, United Kingdom
- Site 2002 - Madrid, Spain
- Site 2005 - Madrid, Spain
- Site 2004 - Madrid, Spain
- Site 2011 - Madrid, Spain
- Site 2010 - Manresa, Spain
- Site 1703 - Meldola, Italy
- Site 1201 - Namur, Belgium
- Site 1802 - Otwock, Poland
- Site 1804 - Poznan, Poland
- Site 1801 - Przemyśl, Poland
- Site 1702 - Ravenna, Italy
- Site 2009 - Valencia, Spain
- Site 2015 - Valencia, Spain